FINWIRES · TerminalLIVE
FINWIRES

摩根士丹利下調評級稱,CSX的業績好轉已基本反映在股票估值中。

-- 摩根士丹利週四在電子郵件報告中指出,CSX(CSX)的扭虧為盈計畫進展順利,但這些成果已基本反映在其股價中。 這家鐵路貨運供應商在周三晚間公佈了超出預期的第一季財報,但其營收略低於華爾街的預期。根據FactSet發布的財報電話會議記錄顯示,執行長史蒂夫安吉爾在會上表示,公司取得這些業績得益於其在提高效率和精簡成本結構方面所做的努力。 摩根士丹利在致客戶的報告中指出:“在新任首席執行官安吉爾的領導下,公司執行情況良好,生產力提升,效率提高,以及大量在建項目將支撐業務量在本週期內的增長。然而,我們認為,目前的扭虧為盈計劃已基本反映在預期和股價中。” 該券商將CSX股票的評級從“持股觀望”下調至“減持”,但維持其30美元的目標價不變。 CSX股價週四下午交易時段上漲7%,年初至今累計漲幅達27%。 摩根士丹利表示,儘管該公司復甦勢頭良好,但股價漲幅「過大過快」。 “如果沒有新的利多消息,我們認為存在下行風險,尤其是在市場預期不斷攀升、卡車運輸競爭加劇的情況下。” 該券商表示,預計明年年底前不太可能出現任何「實質」的併購進展,這將限制該公司短期內的市場地位。 摩根士丹利表示:“我們將密切關註生產率提升和管道運輸改造的步伐,但隨著市場進入上行週期,我們預計卡車運輸相對於鐵路運輸的競爭將更加激烈,其他鐵路運輸的風險回報比也將更高。” 鐵路營運商聯合太平洋鐵路公司(UNP)週四重申了其全年盈利預期,同時其第一季淨利潤也超出了華爾街的預期。

Price: $45.95, Change: $+2.77, Percent Change: +6.40%

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703